SEC-sourced researchBeta
AXSM
Axsome Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001579428
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 3, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 270,600,000.0000 | Feb 23, 2026 |
| December 2024 | 385,693,000.0000 | Feb 23, 2026 |
| December 2025 | 638,496,000.0000 | Feb 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 638,496,000.0000 | -183,174,000.0000 | -93,405,000.0000 | 689,805,000.0000 | 601,510,000.0000 | Feb 23, 2026 |
| December 2024 | 385,693,000.0000 | -287,216,000.0000 | -128,410,000.0000 | 568,498,000.0000 | 511,483,000.0000 | Feb 23, 2026 |
| December 2023 | 270,600,000.0000 | -239,238,000.0000 | -145,080,000.0000 | — | — | Feb 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $638.5M | December 2025 | Feb 23, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $385.69M | December 2024 | Feb 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$183.17M | December 2025 | Feb 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$93.41M | December 2025 | Feb 23, 2026 | 10-K |
| Total assetsAssets | $689.81M | December 2025 | Feb 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $601.51M | December 2025 | Feb 23, 2026 | 10-K |